Evolent Health vs Gartner
EVH and IT side by side, both in management and public relations services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EVH and IT compare
Gartner is the larger company, worth 30 times as much as Evolent Health ($14.4B against $486M).
Gartner grew revenue faster over the last twelve months (0.68% versus −4.5% for Evolent Health).
Gartner keeps more of each dollar of sales as profit, with a net margin of 12.0% compared with −24.1% at Evolent Health.
Gartner scores higher on the StockData Score (14 against 7 for Evolent Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EVH | IT |
|---|---|---|
| Size and price | ||
| Market cap | $486M | $14.4B |
| Share price | $4.30 | $228.79 |
| Change, 1 year | −39.3% | −8.4% |
| Change, 5 years | −85.5% | −31.0% |
| Beta (5Y) | 0.81 | 0.94 |
| Employees | 4,200 | 20K |
| StockData Score | ||
| Total score | 7 | 14 (better) |
| Valuation score | 3 | 5 (better) |
| Growth score | 3 (better) | 1 |
| Performance score | 0 | 5 (better) |
| Health score | 1 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 20.5× |
| P/S | 0.2× (better) | 2.2× |
| P/B | 1.3× | – |
| EV/EBITDA | – | 12.2× |
| Fair value | $11.93 | $311.64 |
| Margin of safety | 63.9% (better) | 26.6% |
| Growth | ||
| Revenue growth (TTM) | −4.5% | 0.68% (better) |
| Revenue growth, 5Y average | 15.2% (better) | 9.6% |
| Net income growth (TTM) | – | −38.7% |
| EPS growth (TTM) | – | −31.4% |
| EPS growth, 5Y average | – | 26.7% |
| Profitability | ||
| Gross margin | 17.2% | 70.1% (better) |
| Operating margin | −20.4% | 17.3% (better) |
| Net margin | −24.1% | 12.0% (better) |
| Return on equity | −79.0% | 114% (better) |
| Return on invested capital | −24.1% | 53.8% (better) |
| Financial health | ||
| Debt / equity | 2.52 | – |
| Net debt / EBITDA | – | 1.14 |
| Interest coverage | −6.2× | 7.8× (better) |
| Current ratio | 1.24 (better) | 0.88 |
| Altman Z-score | −0.37 | 3.92 (better) |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Buyback yield | – | 18.2% |
| Shareholder yield | 0.00% | 18.2% (better) |
| Ownership | ||
| Held by institutions | 99.3% | 119% |
| Held by insiders | 3.3% | 3.6% |
| Insider net buying, 12 months | −$291K | $8.4M (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 11.8% | 11.4% |
Go deeper
- EVH stock overview
- EVH income statement
- EVH valuation and score
- IT stock overview
- IT income statement
- IT valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.